Trials / Completed
CompletedNCT05809596
HEAL-LAA Clinical Trial
HEAL-LAA: Post-Market Real World Outcomes in WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 949 (actual)
- Sponsor
- Boston Scientific Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to collect real-world data on WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device in patients with non-valvular atrial fibrillation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | WATCHMAN FLX Pro LAAC Device | Treatment with a WATCHMAN FLX Pro Left Atrial Appendage Closure Device |
Timeline
- Start date
- 2023-10-03
- Primary completion
- 2024-07-15
- Completion
- 2025-09-18
- First posted
- 2023-04-12
- Last updated
- 2025-11-04
- Results posted
- 2025-10-15
Locations
45 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05809596. Inclusion in this directory is not an endorsement.